The dawn of 2026 has witnessed a breakthrough in oncology clinics as liquid biopsy transitions from a secondary monitoring tool to a primary diagnostic standard for solid tumors. In specialized centers from London to Tokyo, researchers are reporting that the ability to detect circulating tumor DNA with ultra-sensitivity is allowing for the diagnosis of malignancies months before they become...
Dutch 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Italiano
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt